Xarelto
(Rivaroxaban)ApprovedSmall molecule
Rivaroxaban is a blood thinner used to prevent dangerous blood clots that can cause strokes or serious bleeding, and to treat existing blood clots in the legs or lungs.[2] Xarelto is currently approved and in use across 65 indications[4].[1]
Xarelto is one of 1107 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
65
Indications
413
Total Trials
31
Active Trials
1,106
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 64 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Xarelto
WWim Janssens
Approved
Proventil
Mylan Pharmaceuticals IncPreclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Olokizumab
UCBPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Conventional
PPopulation Health Research Institute
Preclinical
DAS181
AAnsun Biopharma, Inc.
Preclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation34 trials
Show 31 more trials
Rivaroxaban30 trials
Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
Unknown status·—·Phase 1·NCT05308030·100 enrolled
Show 27 more trials
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07195812·60 enrolled
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Completed·—·Phase 1·NCT04767776·12 enrolled
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population
Recruiting·—··NCT06371170·20 enrolled
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02376010·110 enrolled
Venous Thromboembolism9 trials
Direct Oral Anticoagulants and Venous Thromboembolism
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02833987·59,525 enrolled
Show 6 more trials
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Terminated·—·Phase 3·NCT02664155·203 enrolled
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
Unknown status·—·Phase 2·NCT03139487·176 enrolled
Anticoagulant8 trials
Show 5 more trials
Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data
Completed·—··NCT04593056·102,636 enrolled
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
Completed·—··NCT05256797·353,980 enrolled
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
Completed·—··NCT04879407·98,947 enrolled
Anticoagulation8 trials
Anticoagulation for Advanced Cirrhotic Patients After TIPS
Unknown status·—·N/A·NCT03005444·254 enrolled
Show 5 more trials
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04066764·200 enrolled
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2/3·NCT05700266·1,180 enrolled
Prophylactic Anticoagulation for Catheter-related Thrombosis
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04256525·1,640 enrolled
63 more indications
COVID-197 trials
Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial
Completed·—·Phase 4·NCT04394377·615 enrolled
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Terminated·—·Phase 2·NCT04416048·111 enrolled
Show 4 more trials
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
Completed·—··NCT04736901·90 enrolled
COVID-19 Antithrombotic Rivaroxaban Evaluation
Terminated·—·Phase 4·NCT04757857·660 enrolled
Deep Vein Thrombosis7 trials
Venous thrombosis5 trials
Coronary Artery Disease4 trials
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Unknown status·—·Phase 4·NCT02334254·420 enrolled
Pulmonary Embolism4 trials
Show 1 more trial
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
Completed·—·Phase 4·NCT02810704·18,883 enrolled
Acute Coronary Syndrome4 trials
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00809965·15,526 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00809965·15,526 enrolledStroke3 trials
Calcification3 trials
Total Knee Arthroplasty3 trials
Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty
Unknown status·—·Phase 4·NCT02453802·90 enrolled
Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty
Completed·—·Phase 4·NCT03328832·70 enrolled
Total Hip Replacement3 trials
Adult Subject2 trials
Antithrombotic2 trials
DUAL Antithrombotic Therapy in Patients With AF and ACS
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04023630·4,000 enrolled
Ischemic stroke2 trials
Efficacy and Safety2 trials
Antiphospholipid Syndrome2 trials
Antiplatelet2 trials
Complication2 trials
Prophylaxis2 trials
PROphylaxis in NOn Major Orthopaedic Surgery
Terminated·—·Phase 3·NCT02401594·3,608 enrolled
Peripheral Artery Disease2 trials
Ischemia1 trial
Left Atrial Appendage Closure1 trial
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
Active, not recruiting·CCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec·Phase 4·NCT03568890·510 enrolled
Inflammation1 trial
Orthopedic Surgeries1 trial
Oral Anticoagulation1 trial
Gastrointestinal1 trial
Peripartum Cardiomyopathy1 trial
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Recruiting·—·Phase 4·NCT05180773·250 enrolled
End-Stage Renal Disease1 trial
Cardiovascular1 trial
Tics1 trial
Hematologic Malignancies1 trial
Tranexamic Acid1 trial
Elderly Participants1 trial
Atrial Appendage1 trial
Cerebrovascular Event1 trial
Intermittent Claudication1 trial
Portal Hypertension1 trial
Aortic Valve Replacement1 trial
High Risk1 trial
Coronary Artery Ectasia1 trial
Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.
Unknown status·—·Phase 3·NCT05718531·200 enrolled
Membranous Nephropathy1 trial
Rivaroxaban in Idiopathic Membranous Nephropathy
Recruiting·—·Phase 4·NCT07404436·134 enrolled
Fasting Conditions1 trial
Cardiovascular Disease1 trial
Atherosclerotic Plaque1 trial
Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation
Completed·—·Phase 4·NCT05797376·92 enrolled
Chronic Coronary Syndrome1 trial
PK/PD1 trial
Coronary Artery Bypass1 trial
Atherosclerosis1 trial
Hypothermia1 trial
Unspecified7 trials
The DARE Warfarin CER Study
Unknown status·—··NCT03271450·416,000 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 11, 2018
XARELTO
NDA NDA022406
Dec 20, 2021
XARELTO
NDA NDA215859
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Xarelto drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rivaroxaban. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Coagulation Factor X Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens
Patent Landscape[6]
Patent Cliff
Feb 17, 2034
Earliest patent expiration — generic entry possible after this date